AGIOAgios Pharmaceuticals, Inc.
$31.83-16% 1Y
$31.83
$22.3452 weeks$45.49
The financials
Agios Pharmaceuticals, Inc. by the numbers
Agios Pharmaceuticals, Inc. (AGIO) reported revenue of $45M in Q2 2026 (quarter ended Jun 30, 2026), up 259% from the same quarter a year earlier. That came with a gross margin of 93% and net loss of $101M. For the full year FY2025, revenue was $54M (+48% year on year) and net income −$413M. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $45M | $12M | +259% |
| Gross profit | $42M | $11M | +288% |
| Operating income | −$111M | −$127M | n/a |
| Net income | −$101M | −$112M | n/a |
| Diluted EPS | −$1.69 | −$1.93 | n/a |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $0.00
Segment Latestyear on year
On our screens:Most shorted stocks